Dapagliflozin induces apoptosis by downregulating cFILP<sub>L</sub> and increasing cFILP<sub>S</sub> instability in Caki‑1 cells

Jang,Ji Hoon; Lee,Tae-Jin; Sung,Eon-Gi; Song,In-Hwan; Kim,Joo-Young

doi:10.3892/ol.2022.13521

Dapagliflozin induces apoptosis by downregulating cFILP_L and increasing cFILP_S instability in Caki‑1 cells

Authors:
- Ji Hoon Jang
- Tae-Jin Lee
- Eon-Gi Sung
- In-Hwan Song
- Joo-Young Kim
View Affiliations

Affiliations: Department of Anatomy, College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea
Published online on: September 22, 2022 https://doi.org/10.3892/ol.2022.13521
Article Number: 401
Copyright: © Jang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dapagliflozin is a sodium/glucose cotransporter 2 inhibitor used recently to treat patients with type 2 diabetes. A recent study has demonstrated that dapagliflozin induces apoptosis in human renal and breast tumor cells. However, to the best of our knowledge, the molecular mechanism underlying dapagliflozin‑mediated apoptosis in Caki‑1 human renal carcinoma cells has not been elucidated. The present study demonstrated that the dapagliflozin treatment dose‑dependently increased cell death in Caki‑1 cells. Dapagliflozin treatment also induced apoptosis as confirmed by FITC‑conjugated Annexin V/PI staining. Additionally, treatment with dapagliflozin reduced the expression levels of anti‑apoptotic proteins, cellular Fas‑associated death domain‑like interleukin‑1‑converting enzyme‑inhibitory protein (cFLIP)_L and cFLIP_S in Caki‑1 cells. Benzyloxycarbonyl‑Val‑Ala‑Asp‑fluoromethyl‑ketone inhibited dapagliflozin‑induced apoptosis, implying that dapagliflozin‑induced apoptosis is regulated by a caspase‑dependent pathway. By contrast, N‑acetylcysteine had no effect on dapagliflozin‑induced apoptosis and downregulation of cFLIP_L and cFLIP_S expression. Furthermore, overexpression of cFLIP_L, but not cFLIP_S, partially inhibited apoptosis induced by dapagliflozin. cFLIP_L and cFLIP_S mRNA levels remained constant in Caki‑1 cells after treatment with 0, 20, 40, 60, 80 and 100 µM dapagliflozin. Notably, it was confirmed that cFLIP_S protein levels were reduced due to the increased cFLIP_S instability in dapagliflozin‑treated Caki‑1 cells. The present study also demonstrated that dapagliflozin had no effect on HK‑2 normal human kidney cells. Taken together, the present study revealed that dapagliflozin induced apoptosis via the downregulation of cFLIP_L and an increase in cFLIP_S instability, suggesting that dapagliflozin may be a feasible drug candidate for the treatment of human renal cancer.

View Figures

View References

1	Low G, Huang G, Fu W, Moloo Z and Girgis S: Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 8:484–500. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ray RP, Mahapatra RS, Khullar S, Pal DK and Kundu AK: Clinical characteristics of renal cell carcinoma: Five years review from a tertiary hospital in Eastern India. Indian J Cancer. 53:114–117. 2016. View Article : Google Scholar : PubMed/NCBI
3	Jonasch E, Gao J and Rathmell WK: Renal cell carcinoma. BMJ. 349:g47972014. View Article : Google Scholar : PubMed/NCBI
4	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
5	Rabinovitch RA, Zelefsky MJ, Gaynor JJ and Fuks Z: Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol. 12:206–212. 1994. View Article : Google Scholar : PubMed/NCBI
6	Wang X, Zhang H and Chen X: Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2:141–160. 2019.PubMed/NCBI
7	Bakris GL, Fonseca VA, Sharma K and Wright EM: Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int. 75:1272–1277. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mosley JF II, Smith L, Everton E and Fellner C: Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: A drug class overview. P T. 40:451–462. 2015.PubMed/NCBI
9	Gnudi L, Coward RJM and Long DA: Diabetic nephropathy: Perspective on novel molecular mechanisms. Trends Endocrinol Metab. 27:820–830. 2016. View Article : Google Scholar : PubMed/NCBI
10	Xie Z, Wang F, Lin L, Duan S, Liu X, Li X, Li T, Xue M, Cheng Y, Ren H and Zhu Y: An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett. 495:200–210. 2020. View Article : Google Scholar : PubMed/NCBI
11	Kuang H, Liao L, Chen H, Kang Q, Shu X and Wang Y: Therapeutic effect of sodium glucose Co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit. 23:3737–3745. 2017. View Article : Google Scholar : PubMed/NCBI
12	Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, Chen G, Liang Y and Zhang Q: Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. 132:1108212020. View Article : Google Scholar : PubMed/NCBI
13	Kabel AM, Arab HH and Elmaaboud MA: Effect of dapagliflozin and/or L-arginine on solid tumor model in mice: The interaction between nitric oxide, transforming growth factor-beta 1, autophagy, and apoptosis. Fundam Clin Pharmacol. 35:968–978. 2021. View Article : Google Scholar : PubMed/NCBI
14	Shirley S and Micheau O: Targeting c-FLIP in cancer. Cancer Lett. 332:141–150. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ivanisenko NV, Seyrek K, Hillert-Richter LK, König C, Espe J, Bose K and Lavrik IN: Regulation of extrinsic apoptotic signaling by c-FLIP: Towards targeting cancer networks. Trends Cancer. 8:190–209. 2022. View Article : Google Scholar : PubMed/NCBI
16	He MX and He YW: A role for c-FLIP(L) in the regulation of apoptosis, autophagy, and necroptosis in T lymphocytes. Cell Death Differ. 20:188–197. 2013. View Article : Google Scholar : PubMed/NCBI
17	Bagnoli M, Canevari S and Mezzanzanica D: Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol. 42:210–213. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kataoka T: The caspase-8 modulator c-FLIP. Crit Rev Immunol. 25:31–58. 2005. View Article : Google Scholar : PubMed/NCBI
19	Smyth P, Sessler T, Scott CJ and Longley DB: FLIP(L): The pseudo-caspase. FEBS J. 287:4246–4260. 2020. View Article : Google Scholar : PubMed/NCBI
20	Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamäki T, Johnson MS, Sistonen L and Eriksson JE: Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem. 280:27345–27355. 2005. View Article : Google Scholar : PubMed/NCBI
21	Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E and Saetta AA: c-FLIP expression in bladder urothelial carcinomas: Its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology. 63:1198–1204. 2004. View Article : Google Scholar : PubMed/NCBI
22	Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH and Durrant LG: Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res. 13:5070–5075. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ryu BK, Lee MG, Chi SG, Kim YW and Park JH: Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol. 194:15–19. 2001. View Article : Google Scholar : PubMed/NCBI
24	Azad N and Iyer AKV: Reactive oxygen species and apoptosis. Systems biology of free radicals and antioxidants. Laher I: Springer Berlin Heidelberg; Berlin, Heidelberg: pp. 113–135. 2014, View Article : Google Scholar
25	Jan R and Chaudhry GE: Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 9:205–218. 2019. View Article : Google Scholar : PubMed/NCBI
26	Plati J, Bucur O and Khosravi-Far R: Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 3:279–296. 2011. View Article : Google Scholar : PubMed/NCBI
27	Plati J, Bucur O and Khosravi-Far R: Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem. 104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
28	Goldar S, Khaniani MS, Derakhshan SM and Baradaran B: Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 16:2129–2144. 2015. View Article : Google Scholar : PubMed/NCBI
29	Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L and Johnston PG: c-FLIP inhibits chemotherapy–induced colorectal cancer cell death. Oncogene. 25:838–848. 2006. View Article : Google Scholar : PubMed/NCBI
30	Safa AR, Day TW and Wu CH: Cellular FLICE-like inhibitory protein (C-FLIP): A novel target for cancer therapy. Curr Cancer Drug Targets. 8:37–46. 2008. View Article : Google Scholar : PubMed/NCBI
31	Oztürk S, Schleich K and Lavrik IN: Cellular FLICE-like inhibitory proteins (c-FLIPs): Fine-tuners of life and death decisions. Exp Cell Res. 318:1324–1331. 2012. View Article : Google Scholar : PubMed/NCBI
32	Kiraz Y, Adan A, Yandim MK and Baran Y: Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 37:8471–8486. 2016. View Article : Google Scholar : PubMed/NCBI
33	Pfeffer CM and Singh ATK: Apoptosis: A target for anticancer therapy. Int J Mol Sci. 19:4482018. View Article : Google Scholar : PubMed/NCBI
34	Saito T, Okada S, Yamada E, Shimoda Y, Osaki A, Tagaya Y, Shibusawa R, Okada J and Yamada M: Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J. 62:1133–1137. 2015. View Article : Google Scholar : PubMed/NCBI
35	Liu X, Yue P, Schönthal AH, Khuri FR and Sun SY: Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res. 66:11115–11119. 2006. View Article : Google Scholar : PubMed/NCBI
36	Chen S, Liu X, Yue P, Schönthal AH, Khuri FR and Sun SY: CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. Mol Pharmacol. 72:1269–1279. 2007. View Article : Google Scholar : PubMed/NCBI
37	Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR and Sun SY: Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther. 7:3556–3565. 2008. View Article : Google Scholar : PubMed/NCBI
38	Mora-Molina R, Stöhr D, Rehm M and López-Rivas A: cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cells. Cell Death Dis. 13:1112022. View Article : Google Scholar : PubMed/NCBI
39	Yodkeeree S, Sung B, Limtrakul P and Aggarwal BB: Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res. 69:6581–6589. 2009. View Article : Google Scholar : PubMed/NCBI
40	Sheikh BY, Sarker MMR, Kamarudin MNA and Mohan G: Antiproliferative and apoptosis inducing effects of citral via p53 and ROS-induced mitochondrial-mediated apoptosis in human colorectal HCT116 and HT29 cell lines. Biomed Pharmacother. 96:834–846. 2017. View Article : Google Scholar : PubMed/NCBI
41	Kanayama A and Miyamoto Y: Apoptosis triggered by phagocytosis-related oxidative stress through FLIPS down-regulation and JNK activation. J Leukoc Biol. 82:1344–1352. 2007. View Article : Google Scholar : PubMed/NCBI
42	Nitobe J, Yamaguchi S, Okuyama M, Nozaki N, Sata M, Miyamoto T, Takeishi Y, Kubota I and Tomoike H: Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res. 57:119–128. 2003. View Article : Google Scholar : PubMed/NCBI
43	Uthman L, Homayr A, Juni RP, Spin EL, Kerindongo R, Boomsma M, Hollmann MW, Preckel B, Koolwijk P, van Hinsbergh VWM, et al: Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem. 53:865–886. 2019. View Article : Google Scholar : PubMed/NCBI
44	Hu Y, Xu Q, Li H, Meng Z, Hao M, Ma X, Lin W and Kuang H: Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1/2/cPLA2/AA/ROS pathway independent of hypoglycemic. Front Pharmacol. 13:8278962022. View Article : Google Scholar : PubMed/NCBI
45	Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, Ouyang X and Liang Z: The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann Transl Med. 7:4292019. View Article : Google Scholar : PubMed/NCBI
46	Shibusawa R, Yamada E, Okada S, Nakajima Y, Bastie CC, Maeshima A, Kaira K and Yamada M: Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Sci Rep. 9:98872019. View Article : Google Scholar : PubMed/NCBI